Interpace Biosciences (OTCID: IDXG) cut its share count to one-fifth of its prior level overnight. The 1-for-5 reverse stock split became effective at 12:01 a.m. Eastern Time on August 27, 2026, with common stock expected to begin trading on a split-adjusted basis on the OTCID quotation system as of market open that same day, per the company's August 26, 2026 press release on GlobeNewswire.
The pre-split share count stood at approximately 27.7 million, per the August 26, 2026 SEC Form 8-K filing. The post-split share count was not stated in the press release. The company's ticker symbol temporarily changed to IDXGD for 20 trading days beginning on the effective date. The new CUSIP number is 46062X402.
The mechanics of the decision were locked in on August 20, 2026, the same day stockholders at the annual meeting approved granting the Board discretion to effect a reverse split in a range from 1-for-2 to 1-for-10. The Board selected the 1-for-5 ratio that same day. The Certificate of Amendment was filed with the Secretary of State of Delaware on August 25, 2026.
The stated purpose is compliance with Nasdaq Capital Market's minimum bid price requirement. The company disclosed the hurdles plainly in its 8-K: there is no guarantee it will meet the minimum bid price requirement, and even if it does, additional requirements remain — including a $15 million market value of unrestricted publicly held shares.
CEO Tom Burnell framed the move as strategic rather than defensive. "This reverse stock split is a key part of our strategy to uplist our common stock to Nasdaq, which we believe will help support our planned growth and attract a broader range of investors," Burnell said in the August 26, 2026 press release.
This is not the first action taken toward a Nasdaq uplisting. In October 2024, Series B Preferred Stock investors Ampersand Capital Partners and 1315 Capital exchanged their existing Series B Preferred Stock for new Series C Preferred Stock specifically to assist the company in seeking a Nasdaq listing. At that time, the company stated other steps — including meeting stockholder equity and minimum bid price requirements — might still be needed.
On the financial side, per S&P Global data as of June 23, 2026, Interpace carried a market cap of $45.15 million and trailing twelve-month revenue of $36.25 million. Trailing twelve-month profits stood at $23.65 million. Cash stood at $2.65 million with no debt, for net cash of $2.65 million or $0.10 per share.
Interpace provides esoteric molecular diagnostic testing and pathology services, commercializing molecular diagnostic tests and pathology services that help physicians evaluate cancer risk.
What comes next is conditional: Interpace must demonstrate sustained compliance with Nasdaq's minimum bid price threshold and satisfy remaining listing requirements — including the $15 million market value of unrestricted publicly held shares disclosed in the 8-K — before any transfer from OTC to Nasdaq Capital Market can be completed. The company has not announced a target date for that transfer.